Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.77 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | GABRP | O00591 | 1/20 | 0.55 |
| ▸ | GABRD | O14764 | 1/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.55 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.55 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.55 |
| ▸ | GABRE | P78334 | 1/20 | 0.55 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.55 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27261450 | 0.86 | ALDH1A1 (0.75) | ALDH1A1SMN1; SMN2RXFP1RAB9AKDM4E | |
| SCHEMBL2765423 | 0.84 | SMN1; SMN2 (0.76) | ALDH1A1SMN1; SMN2RXFP1RAB9AKDM4E | |
| SCHEMBL4412318 | 0.84 | SMN1; SMN2 (0.76) | ALDH1A1SMN1; SMN2RXFP1RAB9AKDM4E | |
| SCHEMBL4427419 | 0.82 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2RXFP1RAB9AKDM4E | |
| SCHEMBL28330529 | 0.82 | SMN1; SMN2 (0.71) | ALDH1A1SMN1; SMN2RXFP1RAB9AKDM4E | |
| SCHEMBL1550372 | 0.80 | SMN1; SMN2 (0.69) | ALDH1A1SMN1; SMN2RXFP1RAB9AKDM4E | |
| SCHEMBL4434197 | 0.80 | MDM2 (0.67) | ALDH1A1SMN1; SMN2RAB9AKDM4EHPGD | |
| SCHEMBL1542696 | 0.80 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2RXFP1RAB9AHPGD | |
| SCHEMBL19645881 | 0.80 | SMN1; SMN2 (0.69) | ALDH1A1SMN1; SMN2RXFP1RAB9AKDM4E | |
| SCHEMBL2810983 | 0.79 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2RXFP1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| EP-1480954-B1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2008-12-03 | — | — | EP | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| CN-1024317-C | Antifungal agents based on amides containing phenyl group | RHONE POULENC AGROCHIMIE (FR) | 1994-04-27 | — | — | CN | disclosed |
| CN-1040792-A | ANTIFUNGAL AGENTS BASED ON AMIDES CONTAINING PHENYL GROUP | RHONE POULENC AGROCHIMIE (FR) | 1990-03-28 | — | — | CN | disclosed |
| US-4117135-A | NOVEL 5,6,7,8-TETRAHYDRO-5-QUINOLINES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING, A.G. | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | ALDH1A1 2107/4885SMN1; SMN2 3167/4885RXFP1 181/4885 |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | ALDH1A1 787/4885SMN1; SMN2 222/4885RXFP1 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.